If these findings hold up in a larger cohort (or show up in ME patients), it seems like this could be pretty significant. It might also be really interesting to see if LDN or Abilify treatment would change the results in follow up scans on the same patients. Perhaps this could give us some idea...
But when they added in the salt initially, there was a small decrease in impedance, then it returned to baseline for controls and increased significantly over time for patients. The impedance wouldn't increase above the baseline if it was just a matter of the salt content decreasing over time as...
As I understand it, they basically just added a little salt into the sample (which is plasma plus PBMCs). The nano-needle is not really a needle in the injecting sense; it's more of a very thin tube with little sensors sticking out into it.
They say that the change in impedance is probably...
Do you thoughts on what should be looked at? Are there more direct investigations that should be happening that might give more insight into why this electrical effect appears?
The impedance finding does seem like it indicates something is going on. Obviously, they need to figure out if this...
I haven't read the original paper, but this review (The Neuroendocrinology of Chronic Fatigue Syndrome, Cleare, 2003) points out that:
"However, because subjects were chosen specifically to have a blunted cortisol response to ACTH, the authors admit that this may not generalize to all CFS...
Over $1M from OMF to Ron's lab in 2020, about $300,000 last year — so it does look like maybe the work has slowed significantly. They are sending more money to Alain Moreau and Chris Armstrong these days, but what is surprising to me is how much they have on hand — nearly $10M at the end of last...
More importantly, who cares what the device costs if all it tells us is this person is sick in some unspecified way. They've yet to show if the nano-needle indicates ME or just some general state of illness. If all it does is the latter, it doesn't matter what it costs, it isn't going to be...
A strange video, seems they still haven't managed to test the nano-needle on blood from people with other diseases, still talking about making it cheap, but stalled on further development because NIH won't fund the electrical engineering. More on a RBC deformability device, but nothing new...
Reading though the paper again, it looks to me like for this study they had already grouped the participants into the severe ME group in their previous work and only actually carried out the metabolemics work on these 18 with severe ME and the 18 matched controls, so it doesn't look like cherry...
Abstract
A major obstacle to achieving long-term antiretroviral (ART) free remission or functional cure of HIV infection is the presence of persistently infected cells that establish a long-lived viral reservoir. HIV largely resides in anatomical regions that are inaccessible to routine...
While the severe name definitely just confuses things, I don't think comparing the cohort who met IOM or CCC and Fukuda against controls is a bad thing. Some of the patients who only met Fukuda may not actually have the same disease or at least not in the same way as those who also met IOM or...
The two groups of 18 are just the "severe" ME patients and 18 matched controls selected for this specific metabolic investigation. Their previous paper showed 23% meeting any one of the three criteria and 8% more than one criteria at six months. Still a lot, but not 50%.
Darn, too bad about the timing. I think this is slightly different (or narrower) question, i.e. do you have any blood relatives who have or have had ME? Glad to hear there is a potential for follow up at least.
I've often thought that there could be a lot of potential in looking at families...
And the breakthrough infection group was 89% men, so that would probably skew the results significantly as well, since we know women are more likely to have ME-like LC symptoms.
[Edit: Fixed percentage, I was looking at a stratified analysis, not the main one.]
Also worth noting, since this shows quite a lot lower protection than other studies, that the average age of the patients with breakthrough infections was about 63 after adjustments. So these results might not be that applicable to the general population. We already know vaccines are a lot less...
Interesting that in their analysis, vaccination reduces the risk of pulmonary, coagulation and hematologic symptoms by about 50%, but other symptoms, including fatigue, much less. Maybe the symptoms that were reduced more are related to acute Covid severity and the others aren't.
I suspect...
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.